Exclusive: Russia to roll out its first approved COVID-19 drug next week
News Line
Ukraine reports 5,276 new COVID-19 cases Zelensky: Every third Ukrainian considers road construction one of greatest achievements of 2021 Ukraine ready to implement Minsk agreements, but Russia's desire needed - Yermak Michel: EU unanimously agree to roll over economic sanctions against Russia Actions by Ukraine's partners will help prevent worst-case scenario - Zelensky COVID-19 in Ukraine: Health officials confirm 8,899 daily cases as of Dec 17 Macron tells Zelensky he declared support for Ukraine in call with Putin Zelensky, Scholz discuss gas transit through Ukraine after 2024 Ukraine ready for any format of talks with Russia - Zelensky Ukraine’s only journalist in Russia facing extremism charges - lawyer PM Shmyhal: First two applications for investment projects worth $96 million filed Zelensky, PM of Italy discuss security situation around Ukraine President signs off State Budget 2022 London considering all options for responding to Russia's aggression against Ukraine Putin, Biden to hold another round of talks Some 260,000 Ukrainians “victims of human trafficking” over 30 years - prosecutor general Ukraine plans to create center to protect energy infrastructure from cyber attacks No clear idea so far when Normandy Four top diplomats set to meet - German Ambassador Ukraine receives EUR 600M in macro-financial assistance from EU Zelensky holds phone conversation with PM of Israel Ukraine sets new daily COVID vaccination record MFA: European Union has not yet removed Ukraine from list of safe countries Kyiv records 1,023 new COVID-19 cases, 29 deaths G7 ambassadors welcome adoption of law on NABU status Ukraine can increase Covid vaccination rates to 1.5M a week – Liashko

Russia will start giving its first drug approved to treat COVID-19 to patients next week, its state financial backer told Reuters, a move it hopes will ease strains on the health system and speed a return to normal economic life.

Russian hospitals can begin giving the antiviral drug, which is registered under the name Avifavir, to patients from June 11, the head of Russia’s RDIF sovereign wealth fund told Reuters in an interview. He said the company behind the drug would manufacture enough to treat around 60,000 people a month.

There is currently no vaccine for COVID-19, the disease caused by the new coronavirus, and human trials of several existing antiviral drugs have yet to show efficacy.

A new antiviral drug from Gilead (GILD.O) called remdesivir has shown some promise in small efficacy trials against COVID-19 and is being given to patients by some countries under compassionate or emergency use rules.

Avifavir, known generically as favipiravir, was first developed in the late 1990s by a Japanese company later bought by Fujifilm as it moved into healthcare.